Telomir Pharmaceuticals, Inc.
TELO
$2.00
$0.042.04%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 66.44% | 201.37% | 677.72% | 15.95% | 2,510.33% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 14.18% | 169.37% | 529.45% | 3.38% | 296.79% |
| Operating Income | -14.18% | -169.37% | -529.45% | -3.38% | -296.79% |
| Income Before Tax | 65.15% | 68.93% | -250.07% | 6.54% | -1,195.22% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 65.15% | 68.93% | -250.07% | 6.54% | -1,195.22% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 65.15% | 68.93% | -250.07% | 6.54% | -1,195.22% |
| EBIT | -14.18% | -169.37% | -529.45% | -3.38% | -296.79% |
| EBITDA | -- | -- | -- | -- | -- |
| EPS Basic | 67.50% | 71.62% | -220.09% | 14.51% | -1,151.11% |
| Normalized Basic EPS | 67.47% | -44.10% | -220.25% | 14.53% | -1,157.14% |
| EPS Diluted | 67.50% | 71.62% | -220.09% | 14.51% | -1,151.11% |
| Normalized Diluted EPS | 67.47% | -44.10% | -220.25% | 14.53% | -1,157.14% |
| Average Basic Shares Outstanding | 7.18% | 9.46% | 9.27% | 9.27% | 3.25% |
| Average Diluted Shares Outstanding | 7.18% | 9.46% | 9.27% | 9.27% | 3.25% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |